Skip to main content
SpringerLink
Log in

Blutdruckziele bei Patienten mit Diabetes mellitus

Was sind optimale Werte?

Blood pressure targets in patients with diabetes mellitus

What are optimum values?

  • Schwerpunkt
  • Published:
Herz Aims and scope Submit manuscript

Zusammenfassung

Diabetes mellitus und arterielle Hypertonie sind die häufigsten Erkrankungen im Alter. Beide sind wichtige Risikofaktoren für die Entwicklung kardiovaskulärer Komplikationen und mit einer hohen Sterblichkeit verbunden. Beide Erkrankungen werden oft erst spät erkannt. Die Prognose von Patienten mit Diabetes mellitus wird durch eine optimale Einstellung von Blutzucker und Blutdruck günstig beeinflusst, was anhand randomisierter klinischer Studien belegt ist. Bei Patienten mit Diabetes mellitus und einem Blutdruck von mehr als 130/80 mm Hg sollte zunächst eine Lebensstilberatung in Bezug auf Ernährung und Bewegung erfolgen. Eine medikamentöse Blutdrucksenkung wird bei einem Blutdruck von 140/90 mm Hg oder mehr empfohlen.

Abstract

Diabetes mellitus and arterial hypertension are the most prevalent diseases in the aging population. Both are important risk factors for the development of cardiovascular complications and are associated with a high mortality. Both diseases are often first recognized late. The prognosis of patients with diabetes mellitus is favorably influenced by an optimal adjustment of blood sugar and blood pressure, as confirmed in large randomized clinical trials. Patients with diabetes mellitus and a blood pressure >130/80 mm Hg should first receive life style counseling with respect to nutrition and activity. Drug treatment for reduction of blood pressure is recommended for a blood pressure ≥140/90 mm Hg.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes – Langfassung, 1. Auflage. Version 4. 2013, zuletzt geändert: November 2014. https://doi.org/10.6101/AZQ/000213

  2. Williams B, Mancia G, Spiering W et al (2018) 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 39:3021–3104. https://doi.org/10.1093/eurheartj/ehy339

    Article  PubMed  Google Scholar 

  3. World Health Organization (WHO), Global Health Observatory (GHO) data, Raised blood pressure. https://www.who.int/gho/ncd/risk_factors/blood_pressure_prevalence_text/en/. Zugegriffen: 14. Jan. 2019

  4. Cushman WC, Evans GW, Byington RP (2010) Effects of intensive bloodpressure control in type 2 diabetes mellitus. N Engl J Med 362:1575–1585

    Article  Google Scholar 

  5. Katayama S, Hatano M, Issiki M (2018) Clinical features and therapeutic perspectives on hypertension in diabetics. Hypertens Res 41:213–229. https://doi.org/10.1038/s41440-017-0001-5

    Article  PubMed  Google Scholar 

  6. Ferrannini E, Cushman WC (2012) Diabetes and hypertension: the bad companions. Lancet 380:601–610

    Article  Google Scholar 

  7. Kulenthiran S, Ewen S, Böhm M (2017) Hypertension up to date: SPRINT to SPYRAL. Clin Res Cardiol 106:475–484

    Article  Google Scholar 

  8. Salvi P, Safar ME, Labat C et al (2010) PARTAGE Study Investigators. Heart disease and changes in pulse wave velocity and pulse pressure amplification in the elderly over 80 years: the PARTAGE Study. J Hypertens 28:2127–2133

    Article  CAS  Google Scholar 

  9. Rizzoni D, Porteri E, Guelfi D (2001) Structural alterations in subcutaneous small arteries of normotensive and hypertensive patients with non-insulin-dependent diabetes mellitus. Circulation 103:1238–1244

    Article  CAS  Google Scholar 

  10. Ferrannini E, Buzzigoli G, Bonadonna R et al (1987) Insulin resistance in essential hypertension. N Engl J Med 317:350–357

    Article  CAS  Google Scholar 

  11. Hermida RC, Ayala DE, Mojón A et al (2011) Influence of time of day of blood pressure—lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care 34:1270–1276. https://doi.org/10.2337/dc11-029

    Article  PubMed  PubMed Central  Google Scholar 

  12. Timmis A, Townsend N, Gale C (2017) European Society of Cardiology: Cardiovascular Disease Statistics 2017. Eur Heart J 39:508–577. https://doi.org/10.1093/eurheartj/ehx628

    Article  Google Scholar 

  13. Bangalore S, Kumar D, Lobach I et al (2011) Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose observations from traditional and bayesian random-effects Meta-analyses of randomized trials. Circulation 123:2799–2810

    Article  CAS  Google Scholar 

  14. Rashwani A, Rawshani A, Franzén S (2018) Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 379:633–644. https://doi.org/10.1056/NEJMoa1800256

    Article  Google Scholar 

  15. Brunström M, Carlberg B (2016) Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ 352:i717. https://doi.org/10.1136/bmj.i717

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. de Boer IH, Bangalore S, Benetos A et al (2017) Diabetes and hypertension: a position statement by the American Diabetes Association. Diabetes Care 40:1273–1284. https://doi.org/10.2337/dci17-0026

    Article  CAS  PubMed  Google Scholar 

  17. Whelton PK, Carey RM, Aronow WS (2018) ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 71:1269–1324

    Article  CAS  Google Scholar 

  18. Böhm M, Schumacher H, Teo KK (2017) Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet 389:2226–2237. https://doi.org/10.1016/S0140-6736(17)30754-7

    Article  PubMed  Google Scholar 

  19. Böhm M, Schumacher H, Teo KK (2018) Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120–140 mm Hg) and cardiovascular outcomes in high-risk patients: results fromONTARGET and TRANSCEND trials. Eur Heart J 39:3105–3114. https://doi.org/10.1093/eurheartj/ehy287

    Article  PubMed  Google Scholar 

  20. SPRINT Research Group (2015) A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373:2103–2116

    Article  Google Scholar 

  21. Emdin CA, Rahimi K, Neal B et al (2015) Blood pressure lowering in type 2 diabetes a systematic review and meta-analysis. JAMA 313(6):603–615. https://doi.org/10.1001/jama.2014.18574

    Article  CAS  PubMed  Google Scholar 

  22. Kjeldsen SE, Os I, Nilsson PM (2018) Does intensive glucose control cancel out benefits of systolic blood pressure target. Hypertension. https://doi.org/10.1161/HYPERTENSIONAHA.118.11455

    Article  PubMed  Google Scholar 

  23. Mancia G (2010) Effects of intensive blood pressure control in the management of patients with type 2 diabetes mellitus in the action to control cardiovascular risk in diabetes (ACCORD) trial. Circulation 122:847–849

    Article  Google Scholar 

  24. Beddhu S, Chertow GC, Greene T et al (2018) Effects of intensive systolic blood pressure lowering on cardiovascular events and mortality in patients with type 2 diabetes mellitus on standard glycemic control and in those without diabetes mellitus: reconciling results from ACCORD BP and SPRINT. J Am Heart Assoc 7:e9326. https://doi.org/10.1161/JAHA.118.009326

    Article  PubMed  PubMed Central  Google Scholar 

  25. Dutka DP, Pitt M, Pagano D et al (2006) Myocardial glucose transport and utilization in patients with type 2 diabetes mellitus, left ventricular dysfunction, and coronary artery disease. J Am Coll Cardiol 48:2225–2231

    Article  CAS  Google Scholar 

  26. Rydén L, Grant PJ, Anker SD et al (2013) ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34(39):3035–3087

    PubMed  Google Scholar 

  27. Arima H, Chalmers J, Woodward M et al (2006) Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens 24:1201–1208

    Article  CAS  Google Scholar 

  28. Messerli FH, Mancia G, Conti CR et al (2006) Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 144:884–893

    Article  Google Scholar 

  29. Sleight P, Redon J, Verdecchia P et al (2009) Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 27:1360–1369

    Article  CAS  Google Scholar 

  30. Polese A, De Cesare N, Montorsi P et al (1991) Upward shift of the lower range of coronary flow autoregulation in hypertensive patients with hypertrophy of the left ventricle. Circulation 83:845–853

    Article  CAS  Google Scholar 

  31. Waits GS, O’Neal WT, Sandesara PB et al (2018) Association between low diastolic blood pressure and subclinical myocardial injury. Clin Res Cardiol 107(4):312–318. https://doi.org/10.1007/s00392-017-1184-0

    Article  PubMed  Google Scholar 

  32. Zoungas S, deGalan BE, Ninomiya T et al (2009) Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes. Diabetes Care 32:2068–2074

    Article  CAS  Google Scholar 

  33. Wijkman M, Länne T, Engvall J et al (2009) Masked nocturnal hypertension—a novel marker of risk in type 2 diabetes. Diabetologia 52:1258–1264. https://doi.org/10.1007/s00125-009-1369-9

    Article  CAS  PubMed  Google Scholar 

  34. Fogari R, Zoppi A, Malamani GD et al (1993) Ambulatory blood pressure monitoring in normotensive and hypertensive type 2 diabetics. Preval Impair Diurnal Blood Press Patterns. Am J Hypertens 6:1–7

    Article  CAS  Google Scholar 

  35. Nakano S, Fukuda M, Hotta F et al (1998) Reversed circadian blood pressure rhythm is associated with occurrences of both fatal and nonfatal vascular events in NIDDM subjects. Diabetes 47:1501–1506

    Article  CAS  Google Scholar 

  36. Franklin SS, Thijs L, Li Y et al (2013) Masked hypertension in diabetes mellitus. Treatment implications for clinical practice. Hypertension 61:964–971

    Article  CAS  Google Scholar 

  37. Ohkubo T, Imai Y, Tsuji I et al (1998) Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population-based observation in Ohasama, Japan. J Hypertens 16:971–975

    Article  CAS  Google Scholar 

  38. Kamoi K, Miyakoshi M, Soda S et al (2002) Usefulness of home blood pressure measurement in the morning in type 2 diabetic patients. Diabetes Care 25:2218–2223

    Article  Google Scholar 

  39. Toyama M, Watanabe S, Miyauchi T et al (2014) Diabetes and obesity are significant risk factors for morning hypertension: from Ibaragi Hypertension Assessment trial (I-HAT). Life Sci 104:32–37

    Article  CAS  Google Scholar 

  40. American Diabetes Association (2014) Standards of medical care in diabetes. Diabetes Care 37(suppl 1):S14–S80

    Article  Google Scholar 

  41. American Diabetes Association (2019) 10. Cardiovascular disease and risk management: standards of medical care in diabetes—2019. Diabetes Care 42(Supplement 1):S103–S123. https://doi.org/10.2337/dc19-S010

    Article  Google Scholar 

  42. Lewis EJ, Hunsicker LG, Bain RP et al (1993) Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456–1462

    Article  CAS  Google Scholar 

  43. Brenner BM, Cooper ME, de Zeeuw D et al (2001) RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861–869

    Article  CAS  Google Scholar 

  44. Lewis EJ, Hunsicker LG, Clarke WR et al (2001) Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851–860

    Article  CAS  Google Scholar 

  45. Feldt-Rasmussen B, Mathiesen ER, Deckert T et al (1987) Central role for sodium in the pathogenesis of blood pressure changes independent of angiotensin, aldosterone and catecholamines in type 1 (insulindependent) diabetes mellitus. Diabetologia 30:610–617

    CAS  PubMed  Google Scholar 

  46. Raheja P, Price A, Wang Z et al (2012) Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients. Hypertension 60:319–325

    Article  CAS  Google Scholar 

  47. Filippatos G, Anker SD, Böhm M et al (2016) A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J 37:2105–2114

    Article  CAS  Google Scholar 

  48. Baier D, Teren A, Wirkner K (2018) Parameters of pulse wave velocity: determinants and reference values assessed in the population-based study LIFE-Adult. Clin Res Cardiol 107:1050–1061. https://doi.org/10.1007/s00392-018-1278-3

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Universität des Saarlandes, Kirrberger Str., Geb. 41.1, 66421, Homburg/Saar, Deutschland

    J. Dederer, Y. Bewarder, F. Mahfoud & M. Böhm

Authors
  1. J. Dederer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y. Bewarder
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Mahfoud
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Böhm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Dederer.

Ethics declarations

Interessenkonflikt

J. Dederer, Y. Bewarder, F. Mahfoud und M. Böhm geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren. Die beschriebenen klinischen Untersuchungen am Menschen wurden mit Zustimmung der zuständigen Ethikkommission, im Einklang mit nationalem Recht sowie gemäß der Deklaration von Helsinki von 1975 (in der aktuellen, überarbeiteten Fassung) und gemäß der Good Clinical Practice durchgeführt.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dederer, J., Bewarder, Y., Mahfoud, F. et al. Blutdruckziele bei Patienten mit Diabetes mellitus. Herz 44, 231–237 (2019). https://doi.org/10.1007/s00059-019-4796-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00059-019-4796-5

Schlüsselwörter

Keywords

Search

Navigation